Market research
7OT.F Otonomy, Inc
F EUR Not available
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 5M
- P/E ratio
- Not available
- Analyst target
- 6.3
- Dividend yield
- 0.0%
- Beta
- 1.46
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Not available
- Industry
- Not available
- ISIN
- Not available
- Market cap
- 5M
- P/E ratio
- Not available
- Analyst target
- 6.3
- Dividend yield
- 0.0%
- Beta
- 1.46
About
About Otonomy, Inc
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 7OT.F discussion.
5 years, 5 months ago
Otonomy, Inc is currently in a long term downtrend where the price is trading 43.4% below its 200 day moving average.
From a valuation standpoint, the stock is 70.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 387.7.
Otonomy, Inc's total revenue sank by 43.0% to $53K since the same quarter in the previous year.
Its net income has increased by 2.5% to $-11M since the same quarter in the previous year.
Finally, its free cash flow fell by 8.1% to $-8M since the same quarter in the previous year.
Based on the above factors, Otonomy, Inc gets an overall score of 2/5.